Chronic diarrhea caused by idiopathic bile acid malabsorption: an explanation at last

Click to increase image sizeClick to decrease image size

Financial & competing interests disclosure

Alan F Hofmann has served as an ad hoc consultant on two occasions to Daiichi Sankyo Inc., which markets colesevelam in the USA for the treatment of Type II diabetes. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.